scholarly journals Human TCR α/β+CD4−CD8−Double-Negative T Cells in Patients with Autoimmune Lymphoproliferative Syndrome Express Restricted Vβ TCR Diversity and Are Clonally Related to CD8+T Cells

2008 ◽  
Vol 181 (1) ◽  
pp. 440-448 ◽  
Author(s):  
Anne Bristeau-Leprince ◽  
Véronique Mateo ◽  
Annick Lim ◽  
Aude Magerus-Chatinet ◽  
Eric Solary ◽  
...  
2019 ◽  
Vol 144 (2) ◽  
pp. 245-251
Author(s):  
Daniel R. Matson ◽  
David T. Yang

Autoimmune lymphoproliferative syndrome (ALPS) is an inherited nonmalignant lymphoproliferative disorder characterized by heterozygous mutations within the first apoptosis signal receptor (FAS) signaling pathway. Defects in FAS-mediated apoptosis cause an expansion and accumulation of autoreactive CD4− and CD8− (double-negative) T cells, leading to cytopenias, splenomegaly, lymphadenopathy, autoimmune disorders, and a greatly increased lifetime risk of lymphoma. The differential diagnosis of ALPS includes infection, other inherited immunodeficiency disorders, primary and secondary autoimmune syndromes, and lymphoma. The most consistent pathologic feature is a florid paracortical expansion of double-negative T cells in lymph nodes. A presumptive clinical diagnosis can be made from symptoms and a constellation of laboratory test results. However, a definitive diagnosis requires ancillary testing and enables disease subclassification. Recognition of ALPS is critical, as treatment with immunosuppressive therapies can effectively reduce or ameliorate symptoms for most patients.


2016 ◽  
Vol 4 (3) ◽  
pp. 123-126
Author(s):  
Yazan S. Mousa

Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the blood, estimated at around 500 cases worldwide. It is characterized by a dysregulation of T-cells in the immune system, and is caused by a defect in the process that mediates leukocyte apoptosis. This may result in an increased risk of lymphoma and autoimmune diseases. Case: The author reports a case of an 11-year-old male who had been followed up since three years of age for recurrent cytopenias, occurring with intermittent breakouts of purpuric rash, nosebleeds, and prolonged infections. Conclusion: A probable diagnosis was made through criteria based on the First International ALPS workshop of 2009. This includes the presence of circulating double-negative T cells, considered the laboratory marker unique for ALPS. The mainstay of treatment was prednisone, given at doses varying in proportion to the severity of immunocytopenia. osis.


Blood ◽  
2001 ◽  
Vol 97 (10) ◽  
pp. 3161-3170 ◽  
Author(s):  
Uri Lopatin ◽  
Xu Yao ◽  
Richard K. Williams ◽  
Jack J. H. Bleesing ◽  
Janet K. Dale ◽  
...  

Abstract Autoimmune lymphoproliferative syndrome (ALPS) is an inherited disorder in which genetic defects in proteins that mediate lymphocyte apoptosis, most often Fas, are associated with enlargement of lymph nodes and the spleen and a variety of autoimmune manifestations. Some patients with ALPS have relatives with these same apoptotic defects, however, who are clinically well. This study showed that the circulating levels of interleukin 10 (IL-10) were significantly higher (P < .001) in 21 patients with ALPS than in healthy controls. Moreover, the peripheral blood mononuclear cells (PBMCs) and lymphoid tissues of these patients with ALPS contained significantly higher levels of IL-10 messenger RNA (mRNA;P < .001 and P < .01, respectively). By fractionating PBMC populations, disproportionately high concentrations of IL-10 mRNA were found in the CD4−CD8−T-cell population, expansion of which is virtually pathognomonic for ALPS. Immunohistochemical staining showed intense IL-10 protein signals in lymph node regions known to contain CD4−CD8− T cells. Nonetheless, in vitro studies showed no influence of IL-10 on the survival of CD4−CD8− T cells. Overexpression of IL-10 in patients with inherited apoptotic defects is strongly associated with the overt manifestations of ALPS.


2002 ◽  
Vol 104 (1) ◽  
pp. 21-30 ◽  
Author(s):  
Jack J.H. Bleesing ◽  
Margaret R. Brown ◽  
Cynthia Novicio ◽  
David Guarraia ◽  
Janet K. Dale ◽  
...  

2020 ◽  
Vol 108 (3) ◽  
pp. 851-857
Author(s):  
Noé Rodríguez‐Rodríguez ◽  
Giovanna Flores‐Mendoza ◽  
Sokratis A. Apostolidis ◽  
Florencia Rosetti ◽  
George C. Tsokos ◽  
...  

Blood ◽  
2001 ◽  
Vol 98 (8) ◽  
pp. 2466-2473 ◽  
Author(s):  
Jack J. H. Bleesing ◽  
Margaret R. Brown ◽  
Stephen E. Straus ◽  
Janet K. Dale ◽  
Richard M. Siegel ◽  
...  

Abstract Autoimmune lymphoproliferative syndrome (ALPS) type Ia is caused by inherited defects in apoptosis and is characterized by nonmalignant lymphoaccumulation, autoimmunity, and increased α/β+ double-negative T cells (α/β+-DNT cells). This study reports immunophenotypic findings in 166 members of 31 families with ALPS type Ia, associated with genetic mutations in theTNFRSF6 gene encoding Fas. The ALPS type Ia probands (n = 31) and relatives having both a Fas mutation and clinically proven ALPS (n = 28) showed significant expansion of CD8+T cells, α/β+-DNT cells, γ/δ+-DNT cells, CD3+/ HLA-DR+ T cells, CD8+/CD57+ T cells, and CD5+ B cells. Relatives with Fas mutations, but without all the required criteria for ALPS (n = 42), had expansions of CD8+ T cells, α/β+-DNT cells, and γ/δ+-DNT cells. Interestingly, relatives without a Fas mutation and with no features of ALPS (n = 65) demonstrated a small but significant expansion of CD8+ T cells, both DNT cell subsets, and CD5+ B cells. As compared to unrelated healthy controls, lymphocyte subset alterations were greatest in the probands, followed by the relatives with mutations and ALPS. Probands and relatives with mutations and ALPS also showed a lower number of CD4+/CD25+ T cells that, in combination with an independent increase in HLA-DR+ T cells, provided a profile predictive of the presence of clinical ALPS. Because quantitative defects in apoptosis were similar in mutation-positive relatives regardless of the presence of clinical ALPS, factors, other than modifiers of the Fas apoptosis pathway, leading to these distinctive immunophenotypic profiles most likely contribute to disease penetrance in ALPS.


Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 851-860 ◽  
Author(s):  
Anne Rensing-Ehl ◽  
Simon Völkl ◽  
Carsten Speckmann ◽  
Myriam Ricarda Lorenz ◽  
Julia Ritter ◽  
...  

Key Points Lack of KLRG1 and T-bet expression is a unique feature of DNT and subsets of single positive T cells in ALPS patients. Genetic, phenotypic, and transcriptional evidence indicates that DNT in ALPS patients derive from both CD4+ and CD8+ T cells.


Blood ◽  
2009 ◽  
Vol 113 (13) ◽  
pp. 3027-3030 ◽  
Author(s):  
Aude Magerus-Chatinet ◽  
Marie-Claude Stolzenberg ◽  
Maria S. Loffredo ◽  
Bénédicte Neven ◽  
Catherine Schaffner ◽  
...  

Abstract Autoimmune lymphoproliferative syndrome (ALPS) is characterized by splenomegaly, lymphadenopathy, hypergammaglobulinemia, accumulation of double-negative TCRαβ+ CD4−CD8− T cells (DNT cells), and autoimmunity. Previously, DNT cell detection and a functional defect of T cells in a FAS-induced apoptosis test in vitro had been used for ALPS diagnosis. However, a functional defect can also be detected in mutation-positive relatives (MPRs) who remain free of any ALPS-related disease. In contrast, lymphocytes from patients carrying a somatic mutation of FAS exhibit normal sensitivity to FAS-induced apoptosis in vitro. We assessed the soluble FAS-L concentration in the plasma of ALPS patients carrying FAS mutations. Overall, we showed that determination of the FAS-L represents, together with the IL-10 concentration and the DNT cell percentage, a reliable tool for the diagnosis of ALPS.


Sign in / Sign up

Export Citation Format

Share Document